Clinical Trial

A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting

Study acronym: LEPIDOPTERA
Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to describe the clinical and health-related outcomes of amivantamab-containing regimens for the treatment of common epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC; most common type of lung cancer) in a real-world setting. Metastatic NSCLC is when this disease spreads to other parts of body. NSCLC may occur due to mutations (changes) in many genes including epidermal growth factor receptor (EGFR).
Protocol Amendment History 5 changes
notable Trial sites expanded: 75 -> 80 locations 2026-08-01
notable Trial sites expanded: 70 -> 75 locations 2026-07-07
notable Trial sites expanded: 60 -> 70 locations 2026-06-06
notable Trial sites expanded: 48 -> 60 locations 2026-05-09
notable Trial sites expanded: 45 -> 48 locations 2026-04-14
Trial Details
NCT Number NCT07230691
Lead Sponsor Janssen Research & Development, LLC
Conditions Carcinoma, Non-Small-Cell Lung
Enrollment 380 participants
Start Date 2025-12-03
Primary Completion 2030-11-19 (estimated)
Study Completion 2030-12-17 (estimated)
Updated on ClinicalTrials.gov 2026-07-31